

## Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events of special interest was most commonly reported by patients receiving datopotamab deruxtecan for previously treated advanced non-small cell lung cancer (NSCLC) in the Phase III TROPION-Lung01 trial?
  - a. Hyperphosphatemia
  - b. Guillain-Barré syndrome
  - c. Myopericarditis
  - d. Stomatitis
  - e. I'm not sure
2. Which of the following proteins is targeted by the investigational antibody-drug conjugate ifinatamab deruxtecan?
  - a. HER2
  - b. B7-H3
  - c. CDC42
  - d. RET
  - e. I'm not sure
3. Which of the following adverse events of any grade was most commonly observed in patients receiving amivantamab with lazertinib as first-line therapy for advanced NSCLC and an EGFR mutation in the Phase III MARIPOSA trial?
  - a. Confusion
  - b. Paronychia
  - c. Dry mouth
  - d. Blurred vision
  - e. I'm not sure
4. Which of the following targeted therapies has demonstrated clinical activity in patients who experienced disease progression on osimertinib?
  - a. Amivantamab/lazertinib
  - b. Patritumab deruxtecan
  - c. Both a and b
  - d. Neither a nor b
5. An overall survival benefit was observed with adjuvant osimertinib in which of the following patients with completely resected NSCLC and an EGFR mutation?
  - a. Patients with Stage IB disease
  - b. Patients with Stage II disease
  - c. Patients with Stage IIIA disease
  - d. All of the above
  - e. I'm not sure